Spruce Biosciences, Inc.
NASDAQ:SPRBBiotechnology
+$2.47 today
- Market cap
- $117.37M
- Beta
- 3.20
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$27.11
Volume 0.06M
Average 0.06M
SPRB Operating Cash Flow
Cash generated by the company's core business operations during the period.
Spruce Biosciences, Inc.NASDAQ: SPRB
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow declines year over year
Q1 FY2026 operating cash flow of $8.73M (cash outflow) fell 31.4% year over year, ahead of the -45.4% change in trailing-twelve-month operating cash flow. Sequentially, it rose 35.3% from the prior quarter. Over 3 fiscal years it compounded at -7.2% a year.
Context
- Operating cash flow grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -31.4% holds above the trailing-twelve-month pace of -45.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (33.33M) USD
- Year-over-year change
- +40.4%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (33.33M) | +40.4% |
| FY2024 | 2024-12-31 | (55.96M) | -68.2% |
| FY2023 | 2023-12-31 | (33.28M) | +20.2% |
| FY2022 | 2022-12-31 | (41.68M) | -16.2% |
| FY2021 | 2021-12-31 | (35.88M) | — |
Operating Cash Flow vs competitors
How SPRB compares with its peers on the latest reported figures
- SPRB's LTM Mar 2026 operating cash flow of $29.33M is the 3rd largest of the 9 companies compared; the peer median is $17.12M.
- Its year-over-year change of -45.4% is the 7th highest of 9, against a peer median of -12.0%.
- Over three fiscal years its annual growth of -7.2% compares with a peer median of +16.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.05M | -26.5% | -2.9% | 14121.8% | |
| LTM Jun 2026 | $30.15M | -50.4% | +14.1% | 143.6% | |
| LTM Mar 2026 | $29.33M | -45.4% | -7.2% | — | |
| LTM Mar 2026 | $24.46M | -29.6% | -19.6% | 74.7% | |
| LTM Mar 2026 | $18.88M | +2.6% | +37.6% | — | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | $15.36M | +52.3% | +1454.2% | — |
| LTM Mar 2026 | $14.93M | +38.8% | -29.2% | 651.0% | |
| LTM Mar 2026 | $10.41M | -56.0% | +18.3% | 28.3% | |
| LTM Mar 2026 | $8M | +12.4% | +30.4% | 565.5% | |
| Peer median (excluding SPRB) | $17.12M | -12.0% | +16.2% | 354.5% | |
Competitors are the stored peer set for SPRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (42.29M) | (46.18M) | (47.92M) | (53.04M) | (38.97M) |
| Depreciation & Amortization | 68K | 74K | 70K | 46K | 21K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.96M | 3.63M | 4.62M | 5.35M | 2.57M |
| Change in Working Capital | 1.96M | 1.13M | 10.36M | (8.57M) | (724K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (805K) | (1.4M) | 1.91M | (2.04M) | (352K) |
| Other Working Capital | 2.76M | 2.53M | 8.45M | (6.53M) | (372K) |
| Other Non-Cash Items | 434K | (340K) | (404K) | 249K | 3.77M |
| Operating Cash Flow | (35.88M) | (41.68M) | (33.28M) | (55.96M) | (33.33M) |
| Capital Expenditures | (93K) | (8K) | (7K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (79.08M) | (36.8M) | (11.88M) | 0 | 0 |
| Sales of Investments | 0 | 60.5M | 67.67M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (79.17M) | 23.69M | 55.78M | 0 | 0 |
| Debt Repayment | 220K | 0 | (1.62M) | (1.62M) | (2.06M) |
| Common Stock Issued | 0 | (201K) | 53.62M | 246K | 50M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 423K | (40K) | (2.85M) | (246K) | (4.53M) |
| Financing Cash Flow | 643K | (241K) | 49.14M | (1.62M) | 43.48M |
| Effect of Forex Changes | 0 | 187K | 0 | 0 | 0 |
| Net Change in Cash | (114.4M) | (18.05M) | 71.64M | (57.59M) | 10.15M |
| Free Cash Flow | (35.97M) | (41.69M) | (33.28M) | (55.96M) | (33.33M) |
Spruce Biosciences, Inc.
NASDAQ:SPRB
Intrinsic Alpha fair value
Locked
Current Price
$40.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.